0.8765
0.77%
0.0064
Precedente Chiudi:
$0.8701
Aprire:
$0.87
Volume 24 ore:
403.96K
Relative Volume:
0.52
Capitalizzazione di mercato:
$66.20M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-1.0435
EPS:
-0.84
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
-12.32%
1M Prestazione:
-24.41%
6M Prestazione:
-53.11%
1 anno Prestazione:
-32.81%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CTMX | 0.8781 | 66.20M | 101.21M | -569.00K | -56.88M | -0.84 |
VRTX | 450.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 748.45 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.35 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.78 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | Downgrade | Jefferies | Buy → Hold |
2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
2021-11-15 | Iniziato | BTIG Research | Buy |
2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
2021-03-29 | Iniziato | JP Morgan | Overweight |
2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
2020-06-01 | Downgrade | Jefferies | Buy → Hold |
2020-05-14 | Reiterato | H.C. Wainwright | Buy |
2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
2020-03-04 | Iniziato | Barclays | Equal Weight |
2019-11-20 | Iniziato | Guggenheim | Buy |
2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
2019-06-13 | Iniziato | Mizuho | Buy |
2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
2019-03-11 | Iniziato | Barclays | Overweight |
2018-11-26 | Iniziato | Piper Jaffray | Overweight |
2018-10-15 | Iniziato | Goldman | Neutral |
2018-09-13 | Iniziato | H.C. Wainwright | Buy |
2018-06-01 | Iniziato | SunTrust | Buy |
2018-01-05 | Iniziato | Citigroup | Buy |
2017-09-08 | Iniziato | Wedbush | Outperform |
2017-03-27 | Iniziato | H.C. Wainwright | Buy |
2017-03-02 | Iniziato | Instinet | Buy |
2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com
HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World
HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat
CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times
CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks
CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex
CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):